Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1 3Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Inflammatory Breast Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Endometrial Adenocarcinoma 1Cystadenocarcinoma, Serous 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1Biliary Tract Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Taxes 1Specimen Handling 1Radiotherapy 1Radiation 1Pharmacogenomic Testing 1Pemetrexed 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Adenocarcinoma of Lung × Taxes × Clear all
NCT00021060 2013-02-27

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
842 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡